In a phase 3 trial involving 948 participants with resectable gastric or gastroesophageal junction adenocarcinoma, adding durvalumab to standard chemotherapy (flot) significantly enhanced two-year event-free survival (67.4% vs. 58.5%, p<0.001). The overall survival rate also favored the durvalumab group (75.7% vs. 70.4%, p=0.03). Additionally, the rate of pathological complete response was notably higher in the durvalumab group (19.2% vs. 7.2%). Adverse events were comparable between both groups.
Journal Article by Janjigian YY, Al-Batran SE (…) Tabernero J et 24 al. in N Engl J Med
Copyright © 2025 Massachusetts Medical Society.